Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 1.00 |
| ▸ | AXL | P30530 | 4/20 | 1.00 |
| ▸ | MERTK | Q12866 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736523 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736570 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736602 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736850 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736163 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736610 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736605 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736566 | 1.00 | PIK3CD (1.00) | PIK3CDAXLMERTK | |
| SCHEMBL14736782 | 0.94 | PIK3CD (0.88) | PIK3CDAXLMERTK | |
| SCHEMBL14736887 | 0.94 | PIK3CD (0.88) | PIK3CDAXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | claimed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2021-04-01 | — | — | US | claimed |
| EP-3795152-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | claimed |
| CN-111494386-A | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors | 因赛特公司 | 2020-08-07 | — | — | CN | claimed |
| US-20190040067-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE HOLDINGS CORPORATION | 2019-02-07 | — | — | US | claimed |
| EP-3196202-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | claimed |
| EP-3129021-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2017-02-15 | — | — | EP | claimed |
| EP-2751109-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | claimed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | claimed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | claimed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | claimed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4233869-A2 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233869-A2 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| EP-3632442-B1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | INCYTE HOLDINGS CORP (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| EP-4086259-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220119393-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2022-04-21 | — | — | US | disclosed |
| US-20220106318-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2022-04-07 | — | — | US | disclosed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20210332059-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332059-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2021-10-28 | — | — | US | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2021-04-01 | — | — | US | disclosed |
| EP-3795152-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3513793-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3513793-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2021001743-A1 | TRANSLATION INHIBITORS AND USES THEREOF | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3129021-B1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORP (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111494386-A | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors | 因赛特公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-10675284-B2 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | INCYTE CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675284-B2 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | INCYTE CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3632442-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632442-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-106413716-B | Treatment of B cell malignancies by combination of JAK and PI3K inhibitors | 因赛特公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10376513-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376513-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3513793-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3513793-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20190040067-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE HOLDINGS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20190040067-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE HOLDINGS CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-20180344740-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2018-12-06 | — | — | US | disclosed |
| US-10092570-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-10065963-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| US-10064866-B2 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | INCYTE CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| US-10053465-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2018-08-21 | — | — | US | disclosed |
| US-10005788-B2 | Bicyclic fused pyrimidine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005788-B2 | Bicyclic fused pyrimidine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2018-06-26 | — | — | US | disclosed |
| US-9932341-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders | INCYTE CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932341-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders | INCYTE CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180009815-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3196202-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3196202-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708333-B2 | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708333-B2 | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| WO-2017035366-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035366-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2017-03-02 | — | — | US | disclosed |
| WO-2017027717-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044164-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-02-16 | — | — | US | disclosed |
| US-20170044164-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-02-16 | — | — | US | disclosed |
| WO-2017027717-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-3129021-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Corporation (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2751109-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (44 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20220119393-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | PIK3CD 1/4885AXL 1327/4885MERTK 1795/4885 |
| US-10005788-B2 | Bicyclic fused pyrimidine compounds as TAM inhibitors | TK1, NME1, NME2 | PIK3CD 81/4885AXL 31/4885MERTK 12/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20180009815-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | TK1, NME1, NME2 | PIK3CD 81/4885AXL 31/4885MERTK 12/4885 |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | PIK3CD 76/4885AXL 25/4885MERTK 2/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885AXL 2982/4885MERTK 2733/4885 |
| US-10092570-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | PIK3R5, PIK3CA, PIK3CD | PIK3CD 3/4885AXL 955/4885MERTK 1488/4885 |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | PIK3CD 1/4885AXL 1327/4885MERTK 1795/4885 |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | PIK3CD 76/4885AXL 25/4885MERTK 2/4885 |
| US-20190134040-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
| US-10064866-B2 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-10053465-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | PIK3CD 76/4885AXL 25/4885MERTK 2/4885 |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20210093638-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20210332059-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | PIK3CD 76/4885AXL 25/4885MERTK 2/4885 |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-10065963-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | PIK3CD 1/4885AXL 1327/4885MERTK 1795/4885 |
| US-20190040067-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-10376513-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | PIK3CD 76/4885AXL 25/4885MERTK 2/4885 |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | PIK3CD 3/4885AXL 955/4885MERTK 1488/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | PIK3CD 3/4885AXL 955/4885MERTK 1488/4885 |
| US-20170044164-A1 | BICYCLIC FUSED PYRIMIDINE COMPOUNDS AS TAM INHIBITORS | TK1, NME1, NME2 | PIK3CD 81/4885AXL 31/4885MERTK 12/4885 |
| US-10675284-B2 | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20180344740-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | PIK3CD 8/4885AXL 889/4885MERTK 452/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | PIK3CD 3/4885AXL 955/4885MERTK 1488/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885AXL 886/4885MERTK 502/4885 |
| US-20220106318-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | PIK3CD 1/4885AXL 3284/4885MERTK 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.